332 related articles for article (PubMed ID: 29068559)
1. Neuromuscular synapse electrophysiology in myasthenia gravis animal models.
Plomp JJ; Huijbers MGM; Verschuuren JJGM
Ann N Y Acad Sci; 2018 Jan; 1412(1):146-153. PubMed ID: 29068559
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.
van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ
Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models.
Plomp JJ; Morsch M; Phillips WD; Verschuuren JJ
Exp Neurol; 2015 Aug; 270():41-54. PubMed ID: 25620417
[TBL] [Abstract][Full Text] [Related]
4. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
5. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
6. Trans-synaptic homeostasis at the myasthenic neuromuscular junction.
Plomp JJ
Front Biosci (Landmark Ed); 2017 Mar; 22(7):1033-1051. PubMed ID: 28199191
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
[TBL] [Abstract][Full Text] [Related]
8. Homeostatic synaptic plasticity at the neuromuscular junction in myasthenia gravis.
Wang X; Rich MM
Ann N Y Acad Sci; 2018 Jan; 1412(1):170-177. PubMed ID: 28981978
[TBL] [Abstract][Full Text] [Related]
9. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure.
Ghazanfari N; Trajanovska S; Morsch M; Liang SX; Reddel SW; Phillips WD
Ann N Y Acad Sci; 2018 Jan; 1412(1):54-61. PubMed ID: 29125188
[TBL] [Abstract][Full Text] [Related]
10. Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibody.
Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
J Physiol; 2013 May; 591(10):2747-62. PubMed ID: 23440963
[TBL] [Abstract][Full Text] [Related]
11. Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles.
Serra A; Ruff R; Kaminski H; Leigh RJ
Ann N Y Acad Sci; 2011 Sep; 1233():26-33. PubMed ID: 21950972
[TBL] [Abstract][Full Text] [Related]
12. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors.
Morsch M; Reddel SW; Ghazanfari N; Toyka KV; Phillips WD
Exp Neurol; 2012 Oct; 237(2):286-95. PubMed ID: 22789393
[TBL] [Abstract][Full Text] [Related]
13. The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.
Tezuka T; Inoue A; Hoshi T; Weatherbee SD; Burgess RW; Ueta R; Yamanashi Y
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16556-61. PubMed ID: 25368159
[TBL] [Abstract][Full Text] [Related]
14. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
15. Pre- and postsynaptic neuromuscular junction abnormalities in musk myasthenia.
Niks EH; Kuks JB; Wokke JH; Veldman H; Bakker E; Verschuuren JJ; Plomp JJ
Muscle Nerve; 2010 Aug; 42(2):283-8. PubMed ID: 20544919
[TBL] [Abstract][Full Text] [Related]
16. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.
Huijbers MG; Plomp JJ; van Es IE; Fillié-Grijpma YE; Kamar-Al Majidi S; Ulrichts P; de Haard H; Hofman E; van der Maarel SM; Verschuuren JJ
Exp Neurol; 2019 Jul; 317():133-143. PubMed ID: 30851266
[TBL] [Abstract][Full Text] [Related]
17. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies.
Plomp JJ; Huijbers MGM; Verschuuren JJGM; Borodovsky A
J Neurosci Methods; 2022 May; 373():109551. PubMed ID: 35247492
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
[TBL] [Abstract][Full Text] [Related]
19. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
20. The Safety Factor for Neuromuscular Transmission: Effects of Dimethylsulphoxide, Cannabinoids and Synaptic Homeostasis.
Odierna GL; Phillips WD
J Neuromuscul Dis; 2021; 8(5):831-844. PubMed ID: 34334412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
